Director Hershberg sells $125k in Recursion Pharmaceuticals stock

Director Robert Hershberg of Recursion Pharmaceuticals sold 25,000 shares of the company's Class A Common Stock on October 6, 2026. The sale amounted to $125,000, with each share priced at $5.00. At present, the stock trades at $4.27, marking a decline from the sale price. However, shares have seen a 26% gain over the past six months.

Notably, this sale came after Hershberg acquired 25,000 Class A Common Stock shares on the same day, purchasing them at $2.22 per share, totaling $55,500. This acquisition was made in accordance with a Rule 10b5-1 trading plan Hershberg established on December 17, 2025.

In addition to the share sale, Hershberg exercised stock options to purchase another 25,000 shares of Class A Common Stock at an exercise price of $2.22 per share. The shares were granted over time, with one forty-eighth (1/48th) of the shares becoming vested each month starting one month after March 16, 2020.

Following these transactions, Hershberg now directly owns 162,156 shares of Recursion Pharmaceuticals' Class A Common Stock, along with 500,000 stock options. Despite ongoing profitability challenges, the company maintains a Fair financial health rating. Recursion Pharmaceuticals reported its financial results for the second quarter of 2026, revealing a revenue shortfall of $4.48 million, falling short of analysts' expectations.

The company also announced a loss of $0.25 per share, exceeding the anticipated loss of $0.24 per share. In response, Recursion revised its full-year cash operating expense guidance to $375 million. The company's cash balance of approximately $557 million is projected to sustain operations through early 2028. These developments follow a challenging period for Recursion, with shares dropping by 7.9% to $3.05 in premarket trading.